Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Are You Looking for a High-Growth Dividend Stock?
12:50pm, Monday, 17'th Mar 2025
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes?
Novartis CEO says it is watching US reciprocal tariff policy 'very carefully'
01:46am, Monday, 17'th Mar 2025
Swiss pharmaceutical giant Novartis says it is watching "very carefully" how the reciprocal tariff policy proposed by the United States would unfold in early April, Chief Executive Vas Narasimhan said
Dublin, March 14, 2025 (GLOBE NEWSWIRE) -- The "Circulating DNA RNA Patent Landscape Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com's offering. A newly revealed compreh
NFL signs Novartis as first pharmaceutical partner-source
08:03am, Thursday, 13'th Mar 2025
The National Football League has signed its first-ever pharmaceutical partner in a multi-year deal with Switzerland-based firm Novartis , a league source told Reuters on Thursday.
Novartis Pharmaceuticals and Folia Health Partner on Innovative App-Based Study to Assess Real-World Experience of IgA Nephropathy
08:03am, Thursday, 13'th Mar 2025
BOSTON, March 13, 2025 (GLOBE NEWSWIRE) -- Today, Folia Health and Novartis Pharmaceuticals, Inc. proudly announce their collaboration on an innovative, at-home observational real-world evidence initi
3 Top Cancer Biotechs to Keep An Eye On in 2025
09:25am, Friday, 07'th Mar 2025
If the cancer space appeals to you, it's time to consider stocks like Novartis, Exact Sciences and Monte Rosa.
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2025 Annual General Meeting
09:11am, Friday, 07'th Mar 2025
Basel, March 7, 2025 – Novartis shareholders today agreed to the Board of Directors' recommendations for all proposed resolutions at the company's Annual General Meeting (AGM). A total of 1,693 shar
10 Dividend Aristocrat Bargains To Help You SWAN During This Trade War Turmoil
07:00am, Thursday, 06'th Mar 2025
The trade war is causing market volatility, with stocks falling and bonds performing well as investors seek hedges against economic slowdown fears. Dividend aristocrats, particularly low-volatility, d
Novartis not panicking over potential US pharmaceutical tariffs, chairman says
02:55am, Thursday, 06'th Mar 2025
Novartis is not panicking about higher tariffs on pharmaceutical imports that U.S. President Donald Trump could impose, the drug maker's Chairman Joerg Reinhardt said in an interview published on Thur
Final Trade: NVS, XLU, GM
06:24pm, Wednesday, 05'th Mar 2025
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Novartis Gets CHMP Opinion for Label Expansion of Fabhalta
10:41am, Monday, 03'rd Mar 2025
The CHMP recommends granting a marketing authorization to NVS' Fabhalta for the treatment of adults with C3 glomerulopathy, an ultra-rare, progressive kidney disease with no currently approved treatme
3 Dividend Stocks That Are No-Brainer Buys Right Now
05:51am, Saturday, 01'st Mar 2025
It can be difficult to decide which dividend stocks to buy. After all, more than 5,700 of them trade on U.S. stock exchanges.
Two-year efficacy and safety data analyses from Phase III SUNSHINE and SUNRISE trials of continuous Cosentyx® (secukinumab) treatment in HS to be presented New analyses of 52-week data from Phase II
Basel, February 28, 2025 – Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommend
Why Novartis Remains A 'Buy' After Beating Expectations Again
10:09am, Thursday, 27'th Feb 2025
At the end of January, Novartis pleasantly surprised me with its financial results for Q4 2024, which were achieved, in part, due to the strong performance of its oncology franchise. So, sales of Pluv
